Dr. William Makis, a Canadian radiologist and cancer researcher, has popularized a metabolic and repurposed-drug approach to cancer support that has generated significant public interest. This article summarizes what the protocol involves and the important context anyone researching it should keep in mind.
Core Idea Behind the Protocol
The approach centers on combining low-cost, off-patent medications originally developed for other conditions with metabolic and lifestyle strategies, with the stated goal of targeting cancer cell metabolism, reducing inflammation, and supporting the immune system.
Core Principles
- Target cancer metabolism: disrupt the energy production and growth pathways cancer cells rely on.
- Repurpose safe, inexpensive drugs: use off-patent medications with established safety profiles in their original indications.
- Boost immune function: strengthen the body's natural defenses.
- Personalize and monitor: tailor the approach to the individual and adjust based on response.
- Support overall health: address nutrition, inflammation, and quality of life.
Medications Commonly Discussed
The protocol references repurposed medications including Fenbendazole, Mebendazole, Ivermectin, Metformin, Atorvastatin, and Doxycycline — each proposed for a different mechanism (anti-parasitic and anti-proliferative effects, disrupted glucose uptake, anti-inflammatory action, and more).
Supportive Supplements Often Mentioned
- Vitamin D3, Vitamin C, and Zinc
- Melatonin and Curcumin
- Coenzyme Q10 and Omega-3 fatty acids
- Probiotics and digestive enzymes
Lifestyle Strategies
The protocol also emphasizes a low-carb or ketogenic diet, intermittent fasting, regular light exercise, stress reduction, quality sleep, and avoiding processed foods and added sugars.
Important Safety Context
This protocol is not FDA-approved for cancer treatment. It is an independent approach based on Dr. Makis's own research and clinical experience, not a peer-reviewed standard of care. Reports of benefit are largely anecdotal and observational rather than the result of controlled clinical trials. None of the medications referenced are approved specifically for cancer treatment, and using them off-label carries real risks, including drug interactions and side effects.
Bottom Line
Anyone considering this or any repurposed-drug protocol should discuss it in detail with a qualified oncologist or healthcare provider before making changes to their treatment plan. This article is provided for educational and informational purposes only.
Legal Disclaimer: This information is for educational purposes only and is not intended to replace professional medical advice, diagnosis, or treatment. The Makis Protocol is not FDA-approved. Consult your healthcare provider for personalized medical guidance.